127 related articles for article (PubMed ID: 29466258)
1. TIME COURSE OF CHANGES IN OPTIC DISK NEOVASCULARIZATION AFTER A SINGLE INTRAVITREAL BEVACIZUMAB INJECTION.
Falavarjani KG; Habibi A; Khorasani MA; Anvari P; Sadda SR
Retina; 2019 Jun; 39(6):1149-1153. PubMed ID: 29466258
[TBL] [Abstract][Full Text] [Related]
2. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
Ahmadieh H; Nourinia R; Hafezi-Moghadam A; Sabbaghi H; Nakao S; Zandi S; Yaseri M; Tofighi Z; Akbarian S
Br J Ophthalmol; 2019 Jul; 103(7):922-927. PubMed ID: 30150280
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
5. MACULAR CHOROIDAL VOLUME CHANGES AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Palkovits S; Seidel G; Pertl L; Malle EM; Hausberger S; Makk J; Singer C; Osterholt J; Herzog SA; Haas A; Weger M
Retina; 2017 Dec; 37(12):2262-2268. PubMed ID: 28129216
[TBL] [Abstract][Full Text] [Related]
6. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
7. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
Bahrami B; Hong T; Schlub TE; Chang AA
Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
[TBL] [Abstract][Full Text] [Related]
8. Treatment Effects in Retinal Angiomatous Proliferation Imaged with OCT Angiography.
de Jong JH; Braaf B; Amarakoon S; Gräfe M; Yzer S; Vermeer KA; Missotten T; de Boer JF; van Velthoven MEJ
Ophthalmologica; 2019; 241(3):143-153. PubMed ID: 30227415
[TBL] [Abstract][Full Text] [Related]
9. TWELVE-MONTH EFFICACY OF INTRAVITREAL BEVACIZUMAB INJECTION FOR CHRONIC, ATYPICAL, OR RECURRENT CENTRAL SEROUS CHORIORETINOPATHY.
Chung YR; Kim JW; Song JH; Park A; Kim MH
Retina; 2019 Jan; 39(1):134-142. PubMed ID: 29077604
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab in the treatment of diabetic ocular neovascularization.
Ababneh OH; Yousef YA; Gharaibeh AM; Abu Ameerh MA; Abu-Yaghi NE; Al Bdour MD
Retina; 2013 Apr; 33(4):748-55. PubMed ID: 23296048
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy.
Rush RB; Rush SW; Aragon AV; Ysasaga JE
Am J Ophthalmol; 2014 Aug; 158(2):337-44. PubMed ID: 24844972
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab in inflammatory ocular neovascularization.
Mansour AM; Mackensen F; Arevalo JF; Ziemssen F; Mahendradas P; Mehio-Sibai A; Hrisomalos N; Lai TY; Dodwell D; Chan WM; Ness T; Banker AS; Pai SA; Berrocal MH; Tohme R; Heiligenhaus A; Bashshur ZF; Khairallah M; Salem KM; Hrisomalos FN; Wood MH; Heriot W; Adan A; Kumar A; Lim L; Hall A; Becker M
Am J Ophthalmol; 2008 Sep; 146(3):410-416. PubMed ID: 18619571
[TBL] [Abstract][Full Text] [Related]
13. Optical coherence tomography angiography in treated type 2 neovascularization undergoing monthly anti-VEGF treatment.
Parravano M; Querques L; Scarinci F; Giorno P; De Geronimo D; Gattegna R; Varano M; Bandello F; Querques G
Acta Ophthalmol; 2017 Aug; 95(5):e425-e426. PubMed ID: 27496070
[No Abstract] [Full Text] [Related]
14. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
15. PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis.
Christenbury JG; Phasukkijwatana N; Gilani F; Freund KB; Sadda S; Sarraf D
Retina; 2018 Jul; 38(7):1276-1288. PubMed ID: 28723848
[TBL] [Abstract][Full Text] [Related]
16. Features of optical coherence tomography predictive of choroidal neovascularisation treatment response in pathological myopia in association with fluorescein angiography.
Lee DH; Kang HG; Lee SC; Kim M
Br J Ophthalmol; 2018 Feb; 102(2):238-242. PubMed ID: 28600301
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study.
Saviano S; Leon PE; Mangogna A; Tognetto D
Digit J Ophthalmol; 2016; 22(2):46-53. PubMed ID: 27582675
[TBL] [Abstract][Full Text] [Related]
19. A Rare Cause of Type II Neovascularization: Unilateral Retinal Pigment Epithelium Dysgenesis.
Şekeryapan Gediz B
Turk J Ophthalmol; 2020 Jun; 50(3):187-189. PubMed ID: 32631022
[TBL] [Abstract][Full Text] [Related]
20. Antivascular endothelial growth factor bevacizumab for radiation optic neuropathy: secondary to plaque radiotherapy.
Finger PT; Chin KJ
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):789-98. PubMed ID: 21277107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
